Advertisement


Joseph A. Greer, PhD, on Lung Cancer: Telehealth vs In-Person Palliative Care

2024 ASCO Annual Meeting

Advertisement

Joseph A. Greer, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses study findings showing the merits of delivering early palliative care via telehealth vs in person to patients with advanced lung cancer. Using telemedicine in this way may potentially improve access to and more broadly disseminate this evidence-based care model (LBA3).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We've seen tremendous breakthroughs in novel therapeutics for lung cancer, which is incredibly exciting. At the same time, most patients with advanced lung cancer will, at some point along their disease trajectory, experience disabling physical and psychological symptoms, poor quality of life, financial stressors, and often, functional changes and worries about what the future might hold. Their caregivers, their loved ones, their friends and family share in this distress. To address these unmet needs, ASCO and other professional societies have recommended the early integration of palliative and oncology care from the time of diagnosis of advanced cancer. These guidelines are based on evidence from multiple clinical trials demonstrating the efficacy of early palliative care for improving quality of life, mood symptoms, coping, and other key outcomes in this vulnerable population. However, and unfortunately, most patients and their families do not receive this evidence-based care due to multiple barriers, chief among them being the limited availability of specialty trained palliative care clinicians. As our team was conceiving of a way to overcome these barriers, one potential solution that seemed highly feasible and potentially acceptable was the use of telehealth to deliver video visits for early palliative care. Therefore, we constructed a large-scale comparative effectiveness trial to test the delivery of early palliative care, either via video visits or in-person visits, for patients with advanced lung cancer and their families. The primary aim was to assess the equivalence of these two modalities on patient-reported quality of life at 24 weeks. We enrolled 1,250 patients and 548 caregivers, and randomly assigned them in a one-to-one fashion, either to early integrated palliative care delivered via video or early integrated palliative care delivered in person, in clinic. Those patients followed the same protocol in both study groups by meeting with the palliative care clinician at least every four weeks over the course of their illness. In addition, a patient and their caregiver would complete self-report measures of quality of life, satisfaction with care, their mood symptoms, and other self-report measures prior to randomization, and then again every 12 weeks up through 48 weeks. In our analysis of these data, we found that the two study groups demonstrated equivalent effects on patient-reported quality of life at 24 weeks. In addition, patients and caregivers also similarly reported no difference in their satisfaction with care whether the delivery of the care was via video or in person. And lastly, patients and caregivers did not report any differences in their mood symptoms. We are very pleased with these findings showing the equivalence between these two modalities for improving patient's quality of life as well as their caregiver outcomes. These findings have implications for improving access to early integrated palliative care, particularly for patients who live in far distances from their clinics, as well as for those who may be frail or have comorbid conditions that make getting to the clinic very challenging. Our hope is that these findings will inform policy decisions and advocates in trying to ensure the coverage of telehealth services for patients with advanced cancer so that they can continue to receive evidence-based early palliative care.

Related Videos

Leukemia

Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Update on BTK Inhibitors

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses a network meta-analysis showing that zanubrutinib appears to be the most efficacious Bruton’s tyrosine kinase (BTK) inhibitor for patients with high-risk relapsed or refractory chronic lymphocytic leukemia. It offers delayed disease progression and favorable survival and response, compared with alternative BTK inhibitors (Abstract 7048).

 

Clifford A. Hudis, MD, and Karen E. Knudsen, MBA: An ASCO–American Cancer Society Partnership to Benefit Patients

Clifford A. Hudis, MD, CEO of the American Society of Clinical Oncology (ASCO), and Karen E. Knudsen, MBA, CEO of the American Cancer Society, discuss a newly launched collaboration between the organizations to make it simpler for patients to find authoritative cancer information online. The effort creates one of the largest and most comprehensive online resources for credible cancer information, available for free to the public on cancer.org.

 

Multiple Myeloma

Luciano J. Costa, MD, PhD, on Multiple Myeloma: Subgroup Analysis of CARTITUDE-4 on Ciltacabtagene Autoleucel

Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham, discusses recent findings from the CARTITUDE-4 trial showing that, in patients with lenalidomide-refractory functional high-risk multiple myeloma after one prior line of treatment, ciltacabtagene autoleucel improved outcomes vs the standard of care (Abstract 7504).

Lymphoma

David J. Andorsky, MD, on DLBCL and FL: New Data on Use of Subcutaneous Epcoritamab

David J. Andorsky, MD, of the Sarah Cannon Research Institute and Rocky Mountain Cancer Centers, discusses EPCORE NHL-6, an ongoing study of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). As outpatients, the study participants were given subcutaneous epcoritamab-bysp to see whether they could be safely monitored and cytokine-release syndrome appropriately managed in the outpatient setting (Abstract 7029).

Breast Cancer

Lisa A. Carey, MD, and Dejan Juric, MD, on Breast Cancer: Updates From the INAVO120 Trial

Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Dejan Juric, MD, of the Massachusetts General Hospital Cancer Center, discuss phase III findings on first-line use of inavolisib or placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer who relapsed within 12 months of completing adjuvant endocrine therapy (Abstract 1003).

Advertisement

Advertisement




Advertisement